BERLIN (GenomeWeb) – Laboratories at 11 institutions in Europe, Canada, and Japan have tested Thermo Fisher Scientific's Oncomine Lung cfDNA assay and found that it can detect low-level mutations in circulating free DNA control samples with high sensitivity and specificity.

Yesterday at the Association for Molecular Pathology AMP Global Congress in Berlin, Claudia Vollbrecht of the Institute of Pathology at Charité University Medicine Berlin presented the results of the study, which was conducted by the OncoNetwork Consortium, a network of researchers organized by Thermo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.